Ignite Creation Date:
2025-12-24 @ 5:07 PM
Ignite Modification Date:
2026-02-18 @ 11:51 PM
Study NCT ID:
NCT02587650
Status:
TERMINATED
Last Update Posted:
2020-01-27
First Post:
2015-10-23
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
Sponsor:
University of California, San Francisco
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
14859
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None